Abstract 205P
Background
CTCF-binding site (BS) occupancy is plastic, tissue specific and altered in cancer. This principle underlies some fragmentomics methods. We hypothesized that ChIP-Seq of plasma CTCF-cfDNA might identify CTCF-BSs selectively occupied in cancer and that, having removed all nucleosomes or other non-CTCF bound cfDNA by CTCF immunoprecipitation (IP), the presence of cfDNA fragments corresponding to sites selectively CTCF occupied in cancer may be tested for by PCR. We now report a novel liquid biopsy method, and initial results, based on this principle.
Methods
(i) Identification of CTCF-BSs selectively occupied in cancer samples. Plasma samples were collected from healthy volunteers (n=5), and patients with inflammatory conditions (n=5) or cancer (n=5). IP was performed using anti-CTCF coated magnetic beads and immunoprecipitated cfDNA was extracted, amplified and sequenced on an Illumina platform. (ii) We developed specific qPCR assays for 10 CTCF-BS sequences that we observed to be preferentially bound in the plasma of cancer patients vs either inflammatory conditions or healthy subjects. The panel of qPCR assays was tested on CTCF associated cfDNA isolated from plasma samples (1ml) obtained from patients diagnosed with a variety of common solid cancer diseases (n=48).
Results
We observed that specific CTCF IP resulted in isolation of cfDNA fragments with a frequency peak in the 30-80bp range that was not present in negative controls (mouse-IgG). These short cfDNA fragments included previously described CTCF binding sites. Moreover, CTCF binding sites were not randomly distributed on cfDNA fragments but located at the centre of each fragment. Among the CTCF occupied binding sites observed, we identified 29 sites that were significantly differentially bound in cancer. We observed highly sensitive and specific qPCR test results for a number of common solid cancer diseases including high sensitivity at disease stage I and II.
Conclusions
This is the first demonstration of IP of plasma CTCF-cfDNA. IP followed by multiplex PCR may form the basis of a rapid, low cost liquid biopsy method that obviates expensive library preparation and NGS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Belgian Volition.
Funding
Belgian Volition.
Disclosure
D. Pamart, J-V. Turatsinze, B. Cuvelier, J-V. Turatsinze: Financial Interests, Personal, Full or part-time Employment: Belgian Volition. M. Herzog: Financial Interests, Personal, Full or part-time Employment: Belgian Volition; Financial Interests, Personal, Stocks/Shares: VolitionRx. J. Micallef: Financial Interests, Personal, Officer, Chief Scientific Officer: VolitionRx Ltd; Financial Interests, Personal, Stocks/Shares: VolitionRx Ltd.
Resources from the same session
185P - Real-world data analysis of genomic profiling-matched targeted therapy outcomes in patients with fusion-positive NSCLC
Presenter: Jyoti Patel
Session: Poster session 01
186P - Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials
Presenter: Marco Tagliamento
Session: Poster session 01
187P - Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 01
188P - The landscape of SMARCA2 genomic alterations in Chinese cancer patients
Presenter: Chen Jiaqi
Session: Poster session 01
189P - Design and enrollment for a classifier development study for a blood-based multi-cancer early detection (MCED) test
Presenter: Christopher Douville
Session: Poster session 01
190P - Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma
Presenter: John Paul Shen
Session: Poster session 01
191P - Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment
Presenter: Kassandra Bisson, Brandon Sheffield
Session: Poster session 01
192P - Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
Presenter: Hussein Sweiti
Session: Poster session 01
194P - Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
Presenter: Dominik Barth
Session: Poster session 01
195P - Identification of biomarkers associated with checkpoint inhibitor pneumonitis based on serum proteomic approach and construction of an online interactive visual prediction model
Presenter: Xiaohui Jia
Session: Poster session 01